FDA Green-Lights Stomach-Stitching Weight-Loss Gadget
Published Date: 5/28/2026
Rule
Summary
The FDA is officially classifying the endoscopic suturing device for weight loss as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this innovative tool faster and ensures it’s safe and effective. The new rules took effect on May 28, 2026, and could save time and money for makers and users alike.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 1 costs, 1 mixed.
Class II Ruling Speeds Patient Access
The FDA classified the endoscopic suturing device for altering gastric anatomy for weight loss into Class II (special controls), effective May 28, 2026, with the classification applicable July 12, 2022. FDA says this lowers regulatory burden compared with automatic Class III assignment and will enhance patient access to the device and similar innovations.
510(k) Premarket Filing Required
The device is subject to premarket notification requirements under section 510(k) of the FD&C Act and FDA has not exempted it. If you plan to market this device, you must submit a 510(k) premarket notification to FDA before marketing.
Mandatory Testing, Training, Labeling Rules
Manufacturers must meet special controls including clinical performance testing (weight change and all adverse events), non-clinical bench testing (functional, dimensional, tensile), shelf-life and sterility data, biocompatibility, user training, and labeling that summarizes clinical performance and shelf life. These requirements are part of the Class II special controls codified at 21 CFR 876.5983.
De Novo Classification Creates Predicate Pathway
FDA classified the device via the De Novo process, meaning this device type can serve as a predicate for future devices; other sponsors can then use the less-burdensome 510(k) route rather than De Novo or PMA for substantially equivalent devices. The De Novo process requires FDA to issue a classification order within 120 days under the statute.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14073 — Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-14119 — Topical Dermatologic Corticosteroids: In Vivo Bioequivalence; Guidance for Industry; Availability
The FDA just released new rules for companies making generic skin creams with steroids. These rules explain how to prove their products work just as well as the original ones by testing on real people’s skin. This update affects drug makers and helps speed up safe, affordable medicine options starting now.
2026-14155 — Considerations for Potential Future Therapeutic Use of Psychedelic Drugs; Public Hearing; Request for Comments
The FDA is hosting a public hearing on September 14, 2026, to explore how psychedelic drugs might be used safely as future medicines. They want to hear from patients, doctors, and anyone interested before October 5, 2026, to help shape rules and support safe, supervised treatments. This could change how some mental health conditions are treated and might open new doors for therapy options.
2026-14158 — Psychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availability
The FDA just released new guidance to help drug makers design safe and smart clinical trials for psychedelic medicines, which could treat mental health and addiction issues. This update affects companies developing these drugs by giving clear rules to follow, speeding up research while keeping safety first. The guidance is effective now, and the FDA welcomes comments anytime, making it easier and clearer to bring these promising treatments to patients.
2026-13820 — Determination That TOVALT ODT (Zolpidem Tartrate) Orally Disintegrating Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that TOVALT ODT tablets (5 mg and 10 mg) weren’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, making it easier and cheaper for people who need this sleep aid. If approved, more affordable options could hit the shelves soon, helping patients and saving money.
Previous / Next Documents
Previous: 2026-10612 — Special Local Regulation; Sail Grand Prix, Upper Bay, New York City, NY
The Coast Guard is setting up a temporary no-go zone in Upper Bay, NYC, for the Sail Grand Prix sailboat race on May 30-31, 2026. Boats and people can’t enter the race area during race hours unless they get special permission. This keeps everyone safe while the super-fast boats zoom around and thousands of fans watch.
Next: 2026-10675 — Medical Devices; Neurological Devices; Classification of the Transcutaneous Electrical Nerve Stimulator To Treat Fibromyalgia Symptoms
The FDA is officially classifying the transcutaneous electrical nerve stimulator for fibromyalgia as a Class II device, meaning it’s safe and effective with some special rules. This change helps patients get easier access to this innovative treatment by cutting down red tape. The new classification is effective May 29, 2026, and could speed up device availability without extra costs for makers or users.